FDA Warns of Reduced Sensitivity for Omicron in Rapid Tests
In a new memo, the United States Food & Drug Administration (FDA) has documented and warned both patients and healthcare providers of the risk of Omicron, the latest variant of SARS-CoV-2, displaying reduced sensitivity to rapid antigen tests. Rapid antigen tests, sometimes referred to as lateral flow tests, are often used in occupational and